All issues > Volume 57(11); 2014

Review Article

Published online: November 30, 2014

DOI: https://doi.org/10.3345/kjp.2014.57.11.465

Current issues of pediatric inflammatory bowel disease in Korea

Seak Hee Oh, MD, Kyung Mo Kim, MD

Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.

Corresponding author: Kyung Mo Kim, MD. Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3380, Fax: +82-2-473-3725, kmkim@amc.seoul.kr

Received September 22, 2014       Accepted October 02, 2014

Copyright © 2014 by The Korean Pediatric Society

(open-access, http://creativecommons.org/licenses/by-nc/3.0/):

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Inflammatory bowel disease (IBD) is a chronic relapsing disorder of unknown etiology, which is believed to be multifactorial. Recently, the incidence of pediatric IBD has steeply increased in Korea since 2000. Poorly controlled disease activity can result in complications such as intestinal fistulae, abscess, and stricture, as well as growth retardation and delayed puberty in children. Because of a lack of confirmative tests, various diagnostic modalities must be used to diagnose IBD. Onset age, location, behavior, and activity are important in selecting treatments. Monogenic IBD must be excluded among infantile and refractory very-early-onset IBD. Early aggressive therapy using biologics has recently been proposed for peripubertal children to prevent growth failure and malnutrition.

Key words: Inflammatory bowel disease, Child, Crohn disease, Ulcerative colitis

Introduction

Introduction

Pediatric inflammatory bowel disease (IBD) was previously rare in Korea¹⁾; therefore, most general pediatricians in Korea may have encountered a few cases of pediatric IBD during their training program. However, the incidence of IBD has risen in adults since 1990²⁾ and in children in the 2000s3,⁴⁾, and its incidence continues to increase without having reached a peak. The incidence of IBD has been rapidly increasing in the last 5 years. General pediatricians are expected to encounter children with IBD more frequently in the near future. To improve the understanding of pediatric IBD among Korean pediatricians, we have written this review focusing on the issues that may pertain to clinical practice in Korea.

What is IBD?

What is IBD?

IBD is a chronic relapsing disorder of unknown etiology that encompasses the two distinct disorders of Crohn disease (CD) and ulcerative colitis (UC). In CD, inflammation can occur anywhere in the gastrointestinal tract. CD, although rarely fatal, is refractory and causes abdominal pain, diarrhea, anorexia, and weight loss (Table 1)3,4,⁵⁾. The clinical presentations of Korean children with CD were similar that observed in Western countries6,7,⁸⁾. In our study, weight loss, growth retardation, lower bone mineral density, and nutritional deficiencies were also observed⁹⁾ (Table 2). Importantly, growth failure is one of the most important aspects in pediatric CD¹⁰⁾. Unlike in the adult population, disease onset in children is uniquely associated with growth retardation and delayed puberty. Poor control of disease activity can result in serious complications such as intestinal fistulae, abscess, and stricture, requiring surgery in both children and adults. The incidence of complications of IBD reported in adult Koreans is lower than that in the West; however, the rate of resection 10 years after the initial diagnosis has recently risen to 32.8%¹¹⁾. In our report, 30.0% of children with IBD required surgeries 10 years after the initial diagnosis¹²⁾. There is currently no medical cure, and the disease is considered a rare, intractable condition that persists throughout a patient's lifetime. Most children with UC in Korea present with hematochezia and diarrhea at the time of diagnosis5,¹³⁾, in line with the observations in Western studies6,7,⁸⁾. Based on the nature of chronic relapsing IBD, early-onset IBD can greatly lower the quality of life, including an inability to work and social maladjustment, in children with IBD. Therefore, better awareness and effective measures for treating pediatric IBD are needed at a societal level.

How does IBD develop?

How does IBD develop?

Understanding of the pathogenesis of IBD is essential for identifying several key points at which intestinal inflammation can be modulated and expanding our treatment options for IBD. The pathogenesis of the disease involves the complex interactions between genetic factors¹⁴⁾, environmental factors15,¹⁶⁾ such as commensal intestinal bacteria, and immunological factors¹⁷⁾. The discordance of IBD among monozygotic twins¹⁸⁾ and the increased incidence of IBD among immigrants to high-prevalence countries indicate an important role of environmental factors in the development of IBD. These factors may cause disruptions in the intestinal microbiota (dysbiosis) and modify the relationships between the human intestinal microbiota and mucosal immune system. The enormous success of tumor necrotic factor-α blockade in IBD treatment, which opened a new era of investigation for the pathogenesis of IBD, suggests that IBD is an autoinflammatory disease of the intestine.

In addition, more than 100 genetic loci, of which variants may alter normal mucosal immunity in the gastrointestinal tract, were uncovered by genome-wide association studies (GWASs) in Western populations19,20,²¹⁾. Recently, a Korean GWAS also identified an extensive overlap of genetic risks with those of Western populations²²⁾. GWASs of pediatric IBD are rare, and only two pediatric GWASs have been conducted, with the studies noting several new loci23,²⁴⁾. However, those loci were replicated in large-scale GWAS meta-analyses in adult populations²¹⁾. Interestingly, despite an extensive overlap of genetic risk with Western populations, nucleotide-binding oligomerization domain (NOD2/CARD15) and autophagy-related 16-like 1 (ATG16L1) have not been associated with IBD in the Korean population, indicating ethnic heterogeneity²²⁾. In addition, we uncovered three new susceptibility loci (ATG16L2, DUSP5, and TBC1D1) in a GWAS of Korean adults and children with IBD. Our other study on pediatric genetics did not find any association with NOD2 mutation²⁵⁾. Variations of TNFSF15, which was demonstrated to have a weak association with IBD in Western populations, was found to greatly contribute to IBD susceptibility in both adults and children in Korea²⁶⁾. This further supports the existence of ethnic differences in the genetics of IBD between populations.

Is the incidence of IBD increasing in Korean adults and children?

Is the incidence of IBD increasing in Korean adults and children?

The global incidence of pediatric CD is not known²⁷⁾. The annual incidence of pediatric CD in Europe and North America is 0.2-8.5 cases per 100,000 people, and that of UC is 0.5-4.3 cases per 100,000 people. Approximately 25%-30% of all cases of CD and 20% of all cases of UC occur in subjects less than 18 years old²⁸⁾. Approximately two decades ago, IBD was considered a rare disease among Korean adults. However, the incidence of IBD started to rise rapidly after the 1990s. A study examining the frequency of IBD in Korean adults illustrated that the prevalence of IBD was 0.05 cases per 100,000 adults in the Gangdong and Songpa districts of Seoul before 1990²⁾, whereas it increased to 1.34 cases per 100,000 adults after 2000. This steep upward trend in the Korean population is reported to be ongoing. This population-based study did not include a national sample; however, it clearly revealed that the incidence of IBD is on the rise in Korean adults. The onset of IBD is reported to be extremely rare in Korean children¹⁾; however, recent single-center studies confirmed that the number of pediatric patients newly diagnosed with CD has increased since 20003,⁴⁾. A population-based study in children is essential to accurately determine whether the incidence of IBD is rising continuously in Korea.

Does the clinical manifestation of IBD in Korean patients differ from that in the West?

Does the clinical manifestation of IBD in Korean patients differ from that in the West?

In our study, most patients with CD (74%) presented with both small bowel and colonic involvement, whereas isolated ileal (13%) and colonic (13%) disease was rare³⁾, as also reported in the Western study of Sawczenko and Sandhu⁷⁾, which found that most patients (84%) had both ileal and colonic involvement and that the dual presentation was more common than observed in a previous report²⁹⁾. These authors considered that isolated colonic disease was more common in the younger children of our study, as noted in a Western report³⁰⁾.

Regarding the location of disease in Korean adults with CD, 66.7%-75.7% of patients had CD in both the small intestine and colon, 10.8%-25.9% exhibited disease in the small intestine, and 7.4%-13.5% displayed disease in the colon, in line with the findings in the pediatric population²⁾. The relatively higher rate of CD in the small intestine and colon as well as the markedly low rate of colonic CD indicates that ethnical differences exist in terms of disease location in adult patients with CD. Moreover, the rate of anal fistula was higher in Korean adults than in Western populations. A study on Korean adults reported that anal fistula was the initial symptom in 15.8% of patients, and the accumulative incidence of anal fistula over 10 years was 49.7%, which is markedly higher than the rates of 13%-38% reported in the West11,³¹⁾. Our study³⁾ also found a higher incidence (50%) of perianal fistula than noted in Western children, including rates of 8% in the work of Kugathasan et al.⁶⁾ and 15% in the study by Palder et al.³²⁾.

Infantile and very-early-onset IBD

Infantile and very-early-onset IBD

According to the Paris classification for pediatric IBD, IBD in subjects less than 10 years old is classified as very-early-onset (VEO) IBD³³⁾. VEO IBD often involves isolated colitis³⁴⁾. The prevalence of anti-Saccharomyces cerevisiae antibody (ASCA) and anti-CBir1 increases and decreases, respectively, until the age of 10 years³³⁾. As VEO IBD has more severe phenotypes and a greater family history, the disease has been postulated to have highly penetrant mutations of Mendelian-like disease. A case of infantile IBD with an IL10R mutation was the first case of a Mendelian form of monogenic IBD³⁵⁾. A recent Korean study also illustrated that as many as 50% of subjects with infantile IBD carried IL10RA mutations³⁶⁾.

Recently, two reviewers identified approximately 50 genes associated with monogenic IBD37,³⁸⁾. Interestingly, three-fourths of these genes are known to be associated with primary immunodeficiency³⁹⁾, for which treatments have not been established with the exceptions of hematopoietic stem cell transplantation and repeated immunoglobulin infusion (Fig. 1). In addition, the diagnosis of these heterogeneous diseases is also challenging because of the limits of conventional evaluations for immunodeficiency in clinical practice. Therefore, whole-exome sequencing (WES) is recommended to diagnose monogenic IBD to avoid a "diagnostic odyssey"37,³⁸⁾. A case of infantile IBD featuring an XIAP mutation was the first example of the application of WES for diagnosing monogenic IBD⁴⁰⁾. However, interpreting variants of unknown significance in WES remains challenging.

Diagnosis and classification of IBD

Diagnosis and classification of IBD

No single unique test or surrogate markers that can diagnose IBD alone exist; therefore, the diagnosis of IBD can be made according to the portfolio for suspected patients through history taking, physical examination, and laboratory, radiologic, endoscopic, and histologic criteria41,⁴²⁾. Detailed diagnostic guidelines were devised for adult Korean patients with IBD43,⁴⁴⁾. Those for pediatric Korean patients have not been created, although they should become available in the near future. First, history taking, physical examination, and laboratory tests for anemia and inflammatory markers should be performed. Then, infectious enteritis or colitis should be excluded. In addition, Korea is an endemic area of tuberculosis; therefore, tuberculosis should be excluded cautiously in children with IBD.

All patients should undergo a full colonoscopy with ileal intubation and mucosal biopsy for histology and culture. We perform esophagogastroduodenoscopy at the time of diagnosis, in addition to radiographic methods such as small bowel series, barium enema, abdominal computed tomography (CT), ultrasonography, and magnetic resonance enterography (MRE) to determine the lesion location and behavior. In the pediatric population, MRE is preferred to CT, as it involves no radiation exposure and it is useful for dynamic studies. MRE is particularly useful in assessing the small intestine; however, we perform capsule endoscopy when MRE alone is not sufficient to confirm lesions confined to the small intestinal mucosa.

The initial evaluation of disease behavior and locations as well as disease activity is important, as it can affect the treatment regimen or selection of medical therapies. We classify the disease status according to the Paris Classification³³⁾. Disease location and behavior such as inflammatory, fistulizing, and stricturing are determined at diagnosis and during follow-up. The presence of any macroscopic abnormality, such as mucosal ulceration, fistula, stricture, or abscess, was considered to indicate regional involvement. The perianal lesions of patients with IBD also include skin tags, fissures, fistulas, and abscesses. In addition, disease activity should be assessed at the time of diagnosis according to the Pediatric Crohn's Disease Activity Index (PCDAI) for CD, which is based on symptoms (30%), physical examination (30%), laboratory parameters (20%), and growth data (20%)⁴⁵⁾. PCDAI scores range from 0 to 100, and they are categorized as follows: no disease activity (<10), mild disease activity (11-30), and moderate to severe disease activity (≥30)⁴⁶⁾. The Pediatric Ulcerative Disease Activity Index (PUCAI) for UC should be also assessed⁴⁷⁾. PUCAI scores range from 0 to 85, and they are categorized as follows: no disease activity (<10), mild disease activity (11-34), moderate disease activity (35-64), and severe disease activity (≥65). In addition to these diagnostic tools, bone densitometry and an evaluation of nutritional status are also needed.

What is the goal in the treatment of IBD?

What is the goal in the treatment of IBD?

In the past, because of the lack of treatment options, the goal of treating IBD was symptom relief to improve quality of life. In children, an additional goal was to prevent growth retardation⁴⁸⁾. However, the recent introduction and aggressive use of biologics has improved patient responses. At present, the primary goal of treatment goes beyond clinical remission to mucosal healing on endoscopy⁴⁹⁾. The endoscopic severity is recognized as the most accurate predictor of forthcoming surgery. It is well known that there is a discrepancy and poor correlation between clinical severity and endoscopic severity⁵⁰⁾. Mucosal healing may not be predicted by CDAI or PCDAI. According to the current understanding of the disease, mucosal damage is accumulated regardless of the clinical disease activity to inflict permanent gastrointestinal damage with a stricturing or penetrating disease⁵¹⁾. Studies in children disclosed similar results. During a mean follow-up period of 36 months, 20% of patients progressed to a stricturing and penetrating disease⁵²⁾.

Step-up therapy has been the mainstay of the treatment algorithm, in which the primary treatment was determined according to the disease activity and behavior to be gradually strengthened when there was no response. Recently, top-down therapy has been considered more effective in patients with at least disease moderate activity53,⁵⁴⁾. However, more scientific evidence is needed to support the use of universal top-down therapy in children. To compensate for the shortcomings of both strategies, targeted early aggressive therapy has recently been proposed. This is a more individualized approach to treating IBD. Siegel et al.⁵⁴⁾ reported that the early use of biologics in high-risk pediatric patients could reduce complications by more than 75%. However, Dubinsky et al.⁵⁵⁾ argued that early aggressive therapy should be conducted in certain patient populations after assessing clinical, immunological, and genetic risk factors. Pediatric patients with poor early responses who enter puberty can experience potential growth retardation before displaying a response to therapy. Top-down therapy may be more beneficial in those patients to minimize the peripubertal accumulation of intestinal damage and avoid underdevelopment from inadequate therapy.

Currently, clinical, serological, and genetic risk factors are being extensively studied to facilitate patient selection. Previously known clinical risk factors of surgical resection of the small intestine and complications include extensive involvement of the small intestine, perianal fistula, young age at diagnosis, and the use of steroids⁵⁶⁾. The presence of antibodies to three bacterial antigens (ASCA, anti-OmpC, and anti-CBir1) has also been reported to be associated with prognosis⁵²⁾. Studies in Western populations reported an association between variations in NOD2/CARD15 with prognosis²⁰⁾; however, this association was not supported in Korean studies25,⁵⁷⁾. Henckaerts et al.⁵⁸⁾ reported over 30 genes associated with susceptibility to IBD. We also found in our study that TNFSF15 was associated with clinical manifestations²⁶⁾. Detailed reviews of the management of IBD were described previously48,⁵⁹⁾. Doctors need to be aware of the rapid changes in the understanding of the pathogenesis and the rapid development and introduction of newer drugs. For example, for anti- tumor necrosis factor-α, as the U.S. Food and Drug Administration (FDA) continues to monitor the safety of this drugs, doctors should pay attention to the results that they are providing (www.fda.gov/cder/drug/early_comm/TNF_blockers.htm).

Growth and nutrition in pediatric CD

Growth and nutrition in pediatric CD

Growth failure is one of the most important aspects of pediatric CD¹⁰⁾. The decrease in height velocity usually occurs before the onset of gastrointestinal symptoms. One-fourth of patients with CD and growth retardation may not achieve their full adult height potential. Therefore, interventions should be initiated before the completion of puberty. First, the disease should be controlled. Second, we must optimize nutrition and minimize corticosteroid use⁶⁰⁾. Interventions are effective if performed in prepubertal patients or in the early stages of puberty. The prevalence of growth retardation at the time of diagnosis in Korean children is approximately 5%, which is less than that reported in a Western report⁹⁾. Severe weight loss and low body mass index were observed in approximately one-third of patients. One-fifth of children already have osteoporosis at the time of diagnosis. In addition, altered nutrition markers for macronutrients as well as micronutrients were highly prevalent at time of diagnosis of CD in Korean children (Table 3).

Conclusions

Conclusions

Understanding the unique features of pediatric IBD is important for its diagnosis and management. First, some clues to the pathogenesis of the disease can be uncovered when we understand the reasons of the current change in the incidence or prevalence between different regions and ethnic backgrounds. Second, we must consider different management strategy when pediatric patients have different characteristics compared to adults.

Poorly controlled disease activity can result in inevitable surgery and growth retardation in children with IBD. Various diagnostic methods in the diagnosis and treatment of IBD have been used to evaluate the locations, behavior, and activity of the disease. Monogenic IBD must be excluded among patients with infantile and refractory VEO IBD. Recently, early aggressive therapy using biologics has recently been proposed for children with IBD who are at great risk of growth failure and malnutrition. A population-based study is needed to accurately estimate the incidence of pediatric IBD in Korea.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

References

1. Seo JK, Yeon KM, Chi JG. Inflammatory bowel disease in children: clinical, endoscopic, radiologic and histopathologic investigation. J Korean Med Sci 1992;7:221–235.
[Article] [PubMed] [PMC]

2. Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542–549.
[Article] [PubMed]

3. Kim BJ, Song SM, Kim KM, Lee YJ, Rhee KW, Jang JY, et al. Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience. Dig Dis Sci 2010;55:1989–1995.
[Article] [PubMed]

4. Lee NY, Park JH. Clinical features and course of crohn disease in children. Korean J Gastrointest Endosc 2007;34:193–199.

5. Choe YH, Lee JH. Diagnosis of inflammatory bowel disease in children. Korean J Pediatr Gastroenterol Nutr 2008;11:S67–S71.

6. Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003;143:525–531.
[Article] [PubMed]

7. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995–1000.
[Article] [PubMed] [PMC]

8. Spray C, Debelle GD, Murphy MS. Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. Acta Paediatr 2001;90:400–405.
[Article] [PubMed]

9. Song SM, Kim Y, Oh SH, Kim KM. Nutritional status and growth in Korean children with Crohn's disease: a single-center study. Gut Liver 2014;8:500–507.
[Article] [PubMed] [PMC]

10. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, Dupas JL, Merle V, Merlin B, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010;105:1893–1900.
[Article] [PubMed]

11. Ye BD, Yang SK, Cho YK, Park SH, Yang DH, Yoon SM, et al. Clinical features and long-term prognosis of Crohn's disease in Korea. Scand J Gastroenterol 2010;4:1178–1185.

12. Kim HJ, Cho JM, Oh SH, Kim KM. Clinical characteristics and outcomes of pediatric Crohn's disease [abstract] In: The 64th Annual Autumn Meeting of the Korean Pediatric Society; 2014 Oct 24-25; Seoul, Korea. Seoul, Korean Pediatric Society. 2014.

13. Cho JM, Kim HJ, Oh SH, Kim KM. Clinical characteristics of ulcerative colitis in Korean children: a single-center experience In: The 2nd Annual Meeting of the Asian Organization for Crohn's & Colitis (AOCC2014); 2014 Jun 19-21; Seoul, Korea. Korean Association for the Study of Intestinal Diseases. 2014.

14. Van Limbergen J, Radford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev Gastroenterol Hepatol 2014;11:372–385.
[Article] [PubMed]

15. Aujnarain A, Mack DR, Benchimol EI. The role of the environment in the development of pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2013;15:326
[Article] [PubMed]

16. Frolkis A, Dieleman LA, Barkema HW, Panaccione R, Ghosh S, Fedorak RN, et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol 2013;27:e18–e24.
[Article] [PubMed] [PMC]

17. Hisamatsu T, Mikami Y, Matsuoka K, Kanai T, Hibi T. Immunological Abnormalities in the Pathogenesis of Inflammatory Bowel Disease. Intest Res 2012;10:317–323.
[Article]

18. Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000;35:1075–1081.
[Article] [PubMed]

19. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246–252.
[Article] [PubMed] [PMC]

20. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118–1125.
[Article] [PubMed] [PMC]

21. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–124.
[Article] [PubMed] [PMC]

22. Yang SK, Hong M, Zhao W, Jung Y, Baek J, Tayebi N, et al. Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. Gut 2014;63:80–87.
[Article] [PubMed]

23. Kugathasan S, Baldassano RN, Bradfield JP, Sleiman PM, Imielinski M, Guthery SL, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 2008;40:1211–1215.
[Article] [PubMed] [PMC]

24. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009;41:1335–1340.
[Article] [PubMed] [PMC]

25. Jang JY, Song SM, Kim KM, Oh SH, Lee YJ, Rhee KW. Lack of common NOD2 mutations in Korean pediatric patients with inflammatory bowel disease. Pediatr Int 2010;52:888–889.
[Article] [PubMed]

26. Lee YJL, Kim KM, Jang JY, Oh SH, Song K. Association of TNFSF15 gene polymorphisms in Korean children with Crohn's disease. Clin Res Hepatol Gastroenterol Forthcoming 2014.

27. Murch SH, Baldassano R, Buller H, Chin S, Griffiths AM, Hildebrand H, et al. Inflammatory bowel disease: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004;39(Suppl 2): S647–S654.
[Article] [PubMed]

28. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999;28:445–458.
[Article] [PubMed]

29. Barton JR, Ferguson A. Clinical features, morbidity and mortality of Scottish children with inflammatory bowel disease. Q J Med 1990;75:423–439.
[Article] [PubMed]

30. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35–40.
[Article] [PubMed]

31. American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 2003;125:1503–1507.
[Article] [PubMed]

32. Palder SB, Shandling B, Bilik R, Griffiths AM, Sherman P. Perianal complications of pediatric Crohn's disease. J Pediatr Surg 1991;26:513–515.
[Article] [PubMed]

33. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314–1321.
[Article] [PubMed]

34. Meinzer U, Idestrom M, Alberti C, Peuchmaur M, Belarbi N, Bellaiche M, et al. Ileal involvement is age dependent in pediatric Crohn's disease. Inflamm Bowel Dis 2005;11:639–644.
[Article] [PubMed]

35. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033–2045.
[Article] [PubMed] [PMC]

36. Shim JO, Seo JK. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations. J Hum Genet 2014;59:337–341.
[Article] [PubMed]

37. Okou DT, Kugathasan S. Role of genetics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014;20:1878–1884.
[Article] [PubMed] [PMC]

38. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, et al. The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease. Gastroenterology 2014;7 21 [Epub]. http://dx.doi.org/10.1053/j.gastro.2014.07.023..

39. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2011;2:54
[PubMed] [PMC]

40. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 2011;13:255–262.
[Article] [PubMed]

41. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1–7.
[Article] [PubMed]

42. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Colitis Foundation of America. Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44:653–674.
[Article] [PubMed]

43. Ye BD, Jang BI, Jeen YT, Lee KM, Kim JS, Yang SK, et al. Diagnostic guideline of Crohn's disease. Korean J Gastroenterol 2009;53:161–176.
[PubMed]

44. Choi CH, Jung SA, Lee BI, Lee KM, Kim JS, Han DS, et al. Diagnostic guideline of ulcerative colitis. Korean J Gastroenterol 2009;53:145–160.
[PubMed]

45. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–447.
[Article] [PubMed]

46. Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416–421.
[Article] [PubMed]

47. Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009;15:1218–1223.
[Article] [PubMed]

48. Lee YJ, Oh SH, Kim KM. The principles of drug therapy of Crohn's disease in child and adolescent. Korean J Pediatr Gastroenterol Nutr 2010;13:S59–S69.
[Article]

49. Wilson DC, Thomas AG, Croft NM, Newby E, Akobeng AK, Sawczenko A, et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2010;50(Suppl 1): S14–S34.
[Article] [PubMed]

50. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811–818.
[Article] [PubMed]

51. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415–1422.
[Article] [PubMed]

52. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008;6:1105–1111.
[Article] [PubMed] [PMC]

53. Lee YS, Baek SH, Kim MJ, Lee YM, Lee Y, Choe YH. Efficacy of early infliximab treatment for pediatric Crohn's disease: a three-year follow-up. Pediatr Gastroenterol Hepatol Nutr 2012;15:243–249.
[Article] [PubMed] [PMC]

54. Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011;17:30–38.
[Article] [PubMed]

55. Dubinsky MC, Kugathasan S, Kwon S, Haritunians T, Wrobel I, Wahbeh G, et al. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. Inflamm Bowel Dis 2013;19:1662–1670.
[Article] [PubMed]

56. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006;130:650–656.
[Article] [PubMed]

57. Lee GH, Kim CG, Kim JS, Jung HC, Song IS. Frequency analysis of NOD2 gene mutations in Korean patients with Crohn's disease. Korean J Gastroenterol 2005;45:162–168.
[PubMed]

58. Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009;7:972–980.e2.
[Article] [PubMed]

59. Kim KM. The pharmacotherapy of inflammatory bowel disease in child and adolescence. J Korean Med Assoc 2010;53:524–530.
[Article]

60. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003;53:205–210.
[Article] [PubMed]

Fig. 1

Overlap among the genes of primary immunodeficiency (PID), very-early-onset (VEO) intestinal bowel disease (IBD)19,20,24,38,³⁹⁾. IBD GWAS, inflammatory bowel disease genome-wide association study.

Table 1

Clinical presentations of Korean children with inflammatory bowel disease

Values are presented as number (%).

CD, Crohn's disease; UC, ulcerative colitis.

Table 2

Distribution of the z scores of various growth parameters at diagnosis in Korean children with Crohn disease⁹⁾

Values are presented as number (%).

SD, standard deviation; BMI, body mass index.

Table 3

Prevalence of subnormal serum levels of various biochemical markers at diagnosis in Korean children with Crohn disease⁹⁾

^*Hemoglobin levels used to define anemia: children 6 months to 5 years, 11.0 g/dL; children 5-11 years, 11.5 g/dL; children 12-13 years, 12.0 g/dL; men, 13.0 g/dL; nonpregnant woman, 12.0 g/dL.